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Statins have pleiotropic properties which are involved in inhibiting the thrombogenic response. In this
study, the effects of lovastatin on two phospholipids, phosphatidylcholine and sphingomyelin, were
studied in cultured endothelial cells in the presence of an oxysterol, 27-hydroxycholesterol. After the
cells were cultured with 50 nM of lovastatin for 60 h, lovastatin was found to decrease the incorporation
of [3H]choline into phosphatidylcholine and sphingomyelin, inhibited CTP: phosphocholine cytidylyl-
transferase (CT) activity without altering the activity of sphingomyelin synthase and neutral sphingo-
myelinase. And lovastatin was not found to have a direct inhibitive effect on activity of CT. Exogenous
mevalonic acid or cholesterol reversed the reduction of cholesterol concentration that was caused by
lovastatin, but had no signiﬁcant effect on the diminished [3H]sphingomyelin by lovastatin. The increase
of [3H]sphingomyelin by 27-hydroxycholesterol was not detected in the presence of lovastatin. These
ﬁndings suggest that (1) lovastatin can reduce sphingomyelin content by means of inhibiting phos-
phatidylcholine synthesis; and (2) The decrease in sphingomyelin is not related to the diminished
cholesterol concentration or mevalonate-derived intermediates. This inhibitive effect of lovastatin on
sphingomyelin may beneﬁt cellular calciﬁcation caused by sphingomyelin.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Oxysterols, present in human serum and lesions, have been
linked to the initiation and progression of atherogenesis [1,2]. 27-
Hydroxycholesterol, one type of oxysterols, is synthesized in the
liver by CYP27A1 as the ﬁrst intermediates of classic and acidic
bile acid synthetic pathways [3] and by non-hepatic cells [4]. It has
been detected in mammalian tissues at very low concentration [5]
and was enriched in pathologic structures such as atherosclerotic
lesions [1,5]. The plasma from patients who had coronary artery
bypass surgery had a higher concentration of 27-hydro-
xycholesterol than that in the plasma from age and sex matched
controls [5]. One of the atherogenic effects of oxysterol was to
enhance sphingomyelin concentration [6]. It is, therefore, not
surprising to observe an increase of both oxysterols and sphin-
gomyelin in atherosclerotic plaque [1,5,7]. And sphingomyelin was
also found to result in a cellular calcium accumulation [6,8] be-
cause of its location on the exterior of the plasma membrane [9];
and its negative charge is accessible to ionic bonding with Caþ þ
[10].r B.V. This is an open access article
row).Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is a
rate-limiting enzyme in the mevalonate pathway. Its inhibitors,
known as statins, have anti-atherogenic effects through reductions
in circulating LDL cholesterol. Besides the reducing effect on de
novo synthesis of cholesterol through blocking HMG-CoA [11],
statins also showed to have pleiotropic effects [12,13], including
the reduction of phospholipids [14]. And the reduced phospholi-
pids by statins were found independent of their decreasing effect
on cholesterol [15,16]; although the decreased mevalonate-de-
rived intermediates were also related to this effect of statins [14]. A
reduced proportion of sphingomyelin and phosphatidylcholine
was detected in the plasma of the patients who took high-dose
(80 mg) simvastatin for 6 weeks [17]. Simvastatin was also ob-
served to reduce lysophosphatidylcholine content in LDL by di-
rectly inhibiting lipoprotein-associated phospholipase A2 [16].
However, there are some inconsistent ﬁndings [18–21]. One study
showed that atorvastatin signiﬁcantly increased phospholipid
content in erythrocyte membrane of guinea pigs [18]; but another
study indicated that atorvastatin reduced the plasma concentra-
tion of phosphatidylcholine in humans [19]. Simvastatin was once
found to raise liver CTP: phosphocholine cytidylyltransferase (CT)
activity in normolipidemic rats [20], but on another occasion it
was not observed to affect this enzyme's activity in normolipi-
demic rabbits [21]. The present study is our further effort inunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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time is on whether lovastatin could reduce sphingomyelin en-
hanced by 27-hydroxycholesterol on cultured vascular endothelial
cells, which are in direct contact with toxicants in the circulation,
and are also involved in atherosclerotic plaque formation.2. Materials and methods
2.1. Materials
[1,2-14C]acetate was obtained from NEN Research Products
(Boston, MA, USA) and [methyl-3H]choline chloride,
[methyl-14C]phosphorylcholine, [methyl-14C]sphingomyelin, and
phosphatidyl[N-methyl-3H]choline were purchased from Amer-
ican Radiolabeled Chemicals, Inc. (St. Louis, MO, USA). 27-Hydro-
xycholesterol was purchased from Research Plus Inc. (Manasquan,
NJ, USA). Lovastatin, mevalonic acid, cholesterol, fetal bovine ser-
um (FBS), Eagle's minimum essential medium (MEM), lipoprotein
deﬁcient serum (LDS), and other reagents were purchased from
Sigma (St. Louis, MO, USA).
The inactive lactone form of lovastatin was converted to the
active form by dissolving 4 mg of lovastatin in 0.1 mL of absolute
ethanol. Then 0.15 mL of 0.1 N NaOH was added. After heating at
50 °C for 2 h, the resulting solution was neutralized with HCl to a
pH of approximately 7.2 and brought up to a volume of 1 mL with
distilled water (Merck Research Laboratories). Stock solution
(10 mM) was stored at 20 °C. The cells were exposed to lovas-
tatin at levels from 5 to 200 nM at designed periods. 27-Hydro-
xycholesterol was dissolved in absolute ethanol at a concentration
of 25 mM and stored at 20 °C. Prior to use, 1 μL of 27-hydro-
xycholesterol in ethanol was ﬁrst dispersed in 20 μL of 0.05% bo-
vine serum albumin and then transferred into the culture medium.
27-Hydroxycholesterol was used at levels of 1.25 and 12.5 μM. The
concentrations of [3H]choline and [14C]acetate were used at levels
of 1 and 2 μCi/mL of culture medium, respectively.
2.2. Cell culture and treatment
Human endothelial cells from umbilical veins were obtained
from American Type Culture Collection (Manassas, VA, USA) and
the passages of the cells used in this study varied from 5 to 13. The
cells were cultured in MEM supplemented with 10% FBS in a 5%
CO2 incubator at 37 °C. When the cells in 25 or 75 cm2 ﬂasks
(Corning Life Sciences, Lowell, MA, USA) had grown to 50% con-
ﬂuences, they were cultured with lovastatin and/or 27-hydro-
xycholesterol in MEM containing 5% LDS for the designed periods.
In the study of cholesterol and phosphatidylcholine synthesis,
[14C]acetate or [3H]choline was added into the dishes prior to 4 h
of culturing with lovastatin.
2.3. Cholesterol concentration and syntheses
For measuring cholesterol concentration, the cellular lipids
were extracted [8] after aliquots were taken for protein assay (Bio-
Rad, Hercules, CA, USA). The lipid extracts were subjected to thin-
layer chromatography on silica gel G plates using hexane: diethyl
ether: acetic acid (85:15:2, v:v:v). Following identiﬁcation with
iodine, the spots of free cholesterol band on plates were quanti-
tatively collected, respectively. The concentrations of cholesterol
were measured [22].
For measuring cholesterol synthesis, the lipid extracts from
[14C]acetate-treated cells were subjected to thin-layer chromato-
graphy as mentioned above. The spots of free cholesterol on plates
were collected and radioactivities were counted. The nonspeciﬁc
activities obtained from some silica gel on blank spaces weresubtracted from sample radioactivity.
2.4. Phosphatidylcholine and sphingomyelin syntheses and sphin-
gomyelin concentration
For measuring incorporation of [3H]choline into phosphati-
dylcholine and sphingomyelin, lipid from [3H]choline-treated cells
were extracted as mentioned above and were subjected to thin-
layer chromatography on silica gel G plates using chloroform:
methanol: acetic acid: water (25:15:4:2, v:v:v:v) [23]. The spots of
phosphatidylcholine and sphingomyelin on the plates were col-
lected and radioactivities were counted. For determining con-
centration of sphingomyelin, the lipid extracts were subjected to
thin-layer chromatography as mentioned above. The spots of
sphingomyelin on the plates were collected and the phosphorus
(Pi) in each sample was then determined.
For measuring whether the inhibited sphingomyelin synthesis
by lovastatin resulted from the reduced cholesterol, 10 μM of
mevalonic acid or 25 μM of cholesterol was used at the same time
lovastatin was added into the ﬂasks. The concentrations of cho-
lesterol and labeled sphingomyelin were determined after 60 h of
the culturing.
2.5. Enzyme activities
For measuring the activity of CT, the cells were washed twice
with normal saline, scraped, and homogenized in 200 μL of
homogenization buffer [24]. Homogenates were sonicated in a
water bath sonicator for 20 min and centrifuged (1000 g) to re-
move cell debris. After 20 μg of protein in supernatant were mixed
with assay buffer containing 50000 cpm of [14C]phosphorylcholine
[24] in a ﬁnal volume of 50 μL, the mixed samples were cultured at
37 °C for 1 h. To stop the reaction, the tubes were immersed in a
boiling water bath for 2 min. Next, 40 μl of each sample was
spotted onto preadsorbent Silica Gel G thin-layer plates and de-
veloped in 95% ethanol: 2% NH4OH (1:1, v:v) [25]. The spots of
CDP-choline on plates were collected. Radioactivities were coun-
ted and calculated. To investigate whether lovastatin has a direct
inhibit effect on CT, supernatants from non-treated cells were
exposed to lovastatin for 5 min before assay buffer was added.
Then the procedure was as performed the same way as mentioned
above.
For determining the activity of phosphatidylcholine: ceramide
phosphocholinetransferase (sphingomyelin synthase), the method
of Vivekananda et al. [26] was used with the following modiﬁca-
tions. In brief, the cells were washed with ice-cold Hanks Balanced
Salt Solution, harvested, lysed in hypotonic cold 1 mM MgCl2 and
homogenized with a Dounce homogenizer. The homogenate was
centrifuged at 1000 g for 5 min and 50 μg of protein in super-
natant were added into an assay buffer containing 10 mM HEPES
(pH 7.4), 3 mM MnCl2, 1% fatty acid-free bovine serum albumin
and 0.05 μCi of phosphatidyl[3H]choline in a total volume of
100 μL. The reaction mixture was cultured for 6 h in a shaking
water bath at 37 °C, terminated by addition of 1 ml of 0.2 M me-
thanolic NaOH and then immediately followed by the addition of
0.5 mL of 0.45 M HCl. The lower organic phase containing sphin-
gomyelin was separated by thin-layer chromatography and
radioactivities were counted.
For assaying the activity of neutral sphingomyelinase (NSMase),
the treated cells were scraped from the ﬂasks, harvested by cen-
trifugation, re-suspended in hypotonic buffer containing 1 mM
NaCO3, 2 mM CaCl2, 1 mM NaHSO3, 1 mM benzamidine and
0.1 mM phenylmethylsulfonyl ﬂuoride. After the cells were soni-
cated for 20 s in ice water, the resultant homogenate (20 μg of
protein) was used for the assays of activity of SMase [27]. Enzy-
matic activity of SMase was measured by the formation of
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The assay mixture for NSMase contained 0.1 M Tris/HCl, pH 7.0,
1 mM dithiothreitol, 10 mM MgCl2, 0.05% Triton X-100, 1.2 M KCl,
22 μM [Nmethyl-14C]sphingomyelin (20,000 cpm), and 20 μg
protein of cell homogenate in a total volume of 50 μL. After in-
cubation for 30 min at 37 °C, reactions were terminated by the
addition of 4 volumes of chloroform/methanol (2:1, v:v). The
radioactivity of phosphocholine recovered from the upper aqueous
layer was determined in a liquid scintillation counter.
2.6. Cytotoxicity
The effects of lovastatin and/or 27-hydroxycholesterol on cell
viability were determined by the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) assay. In brief, after the
cells in 24-well plates were exposed to lovastatin and/or 27-hy-
droxycholesterol, the medium was removed and the cells were
incubated in 540 μL of MEM and 60 μL of 2.5 mg/ml MTT solution
for 4 h at 37 °C. Afterward, the medium with MTT was removed
and 300 μL of dimethyl sulfoxide (DMSO) was added to each well
and plates were shaken for 10 min. Absorbance was read at
570 nm [28]. Viability was expressed as a percentage of absor-
bance of treated cells to untreated cells (control).
2.7. Statistical analysis
Data were subjected to ANOVA and a Student–Newman–Keuls
method. Differences with Po0.05 were considered signiﬁcant. AllFig. 1. Incorporation of [3H]choline into phosphatidylcholine (PC) in the cultured endoth
Lovastatin from 24 to 60 h (C) levels of 27-hydroxycholesterol (27OH) from 1.25 to 12.5
deﬁcient serum in the culture medium. Results are expressed as mean7S.E.M. of duplidata are presented as mean7standard error (S.E.M.).3. Results
To prevent the cells from obtaining cholesterol from the culture
medium, the cells were exposed to lovastatin in lipoprotein-free
medium. Lovastatin induced a dose-dependent decrease in the
incorporation of [3H]choline into phosphatidylcholine after 48 h of
the incubation (Fig. 1A). The incorporation was decreased from
877716 DPM/mg protein (control) to 675711 DPM/mg protein
(200 nM lovastatin). This signiﬁcant decrease started at a con-
centration of 10 nM lovastatin. The inhibited incorporation not
only occurred with the enhanced dose of lovastatin, but also took
place when incubating time was extended. A signiﬁcant inhibition
of incorporation of [3H]choline (752720 DPM/mg protein) was
observed after 48 h in the cells cultured in a medium containing
50 nM of lovastatin, compared with the control (820714 DPM/mg
protein) (Fig. 1B). However, 27-hydroxycholesterol, with the cho-
sen concentrations (Fig. 1C) and the designed incubation periods
(Fig. 1D), had no effect on the incorporation of [3H]choline into
phosphatidylcholine.
The incorporation of [3H]choline into phosphatidylcholine and
sphingomyelin as well as the concentration of sphingomyelin were
altered by administration of lovastatin and 27-hydroxycholesterol
as shown in Fig. 2. Fig. 2A showed that lovastatin inhibited the
incorporation of [3H]choline into phosphatidylcholine. The in-
corporation decreased from 1012723 (control) to 860719 DPM/elial cells treated with (A) levels of lovastatin from 5 to 200 nM for 48 h (B) 50 nM of
mM for 48 h and (D) 2 mM of 27OH from 24 to 60 h in the presence of lipoprotein
cate for each independent determination in eight experiments. *Po0.05.
Fig. 2. Incorporation of [3H]choline into phosphatidylcholine (PC) (A) and sphin-
gomyelin (SM) (B) and the concentration of SM (C) in the cultured endothelial cells
treated with 50 nM of lovastatin (Lov) and/or 2 μM of 27-hydroxycholesterol
(27OH) for 60 h. Results are expressed as mean7S.E.M. of duplicate for each in-
dependent determination in eight experiments. *Po0.05.
Fig. 3. Incorporation of [14C]acetate into cholesterol (A) and the concentration of
cholesterol (B) in the cultured endothelial cells treated with 50 nM of lovastatin
(Lov) and/or 2 μM of 27-hydroxycholesterol (27OH) for 60 h. Results are expressed
as mean7S.E.M. of duplicate for each independent determination in eight ex-
periments. *Po0.05.
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presence of 27-hydroxycholesterol. The incorporation was at
880725 DPM/mg protein in both lovastatin- and 27-hydro-
xycholesterol-treated cells. Lovastatin decreased both incorpora-
tion of [3H]choline into sphingomyelin (from 279713 in untreated
cells to 241715 DPM/mg protein in treated cells) (Fig. 2B) and
sphingomyelin concentration (from 6774.4 in untreated cells to
5672.8 mmol/mg protein in treated cells) (Fig. 2C). In contrast,
27-hydroxycholesterol increased signiﬁcantly the incorporation to
325716 DPM/mg protein and the concentration to
78.375.1 mmol/mg protein. After the addition of lovastatin into
27-hydroxycholesterol-treated cells, the stimulated incorporation
and sphingomyelin concentration caused by 27-hydro-
xycholesterol returned to 264711 DPM/mg protein and
60.173.1 mmol/mg protein, respectively.
The amounts of newly synthesized [14C]cholesterol in both lo-
vastatin- (6672.9 DPM/mg protein) and 27-hydroxycholesterol-
treated (6373.5 DPM/mg protein) cells were decreased, com-
pared with control (12578.2 DPM/mg protein) (Fig. 3A). Similar
changes were observed in cholesterol concentration (Fig. 3B). The
concentration decreased signiﬁcantly to 65.474.4 mmol/mg pro-
tein in lovastatin-treated cells and 73.273.7 mmol/mg protein in
27-hydroxycholesterol-treated cells, compared of 90.174.8 mmol/
mg protein in control. When lovastatin and 27-hydroxycholesterolwere added together, no further decrease of either newly syn-
thesized [14C]cholesterol or cholesterol concentration was ob-
served. These results suggested a similar mechanism of inhibitive
effects on cholesterol synthesis by lovastatin and 27-
hydroxycholesterol.
To eliminate a possible inhibitive effect of cholesterol or me-
valonic acid on the incorporated [3H]choline into sphingomyelin,
mevalonic acid or cholesterol was added to the medium contain-
ing lovastatin. Fig. 4A shows that the decreased concentration
(from 91.174.8 to 66.374.3 mmol/mg protein) of cholesterol
caused by lovastatin was signiﬁcantly reversed by the addition of
cholesterol (83.974.1 mmol/mg protein) or mevalonic acid
(85.173.7 mmol/mg protein). The inhibited incorporation of
[3H]choline into sphingomyelin, however, was not obviously al-
tered (Fig. 4B).
When the cells were exposed to lovastatin, it caused a sig-
niﬁcant reduction of the activity of CT. The CT activity was de-
creased to 2.2270.07 (alone) and 2.0170.11 (with 27-hydro-
xycholesterol) from 2.8570.09 (control), respectively (Fig. 5A).
However, this inhibiting effect of lovastatin on the activity of CT
was not detected when it was added into the supernatant (Fig. 5B).
27-hydroxycholesterol had no effect on the activity of CT (Fig. 5).
The effect of lovastatin on sphingomyelin synthase and NSMase
was shown in Fig. 6. Lovastatin had no effect on the activities of
sphingomyelin synthase (Fig. 6A) and NSMase (Fig. 6B) during the
experimental periods. However, the activity of NSMase was sig-
niﬁcantly inhibited by 27-hydroxycholesterol, from 6273.2
(control) to 4374.1 (alone) and 4573.5 (with lovastatin), re-
spectively (Fig. 6B). The activity of sphingomyelin synthase was
not affected by 27-hydroxycholesterol (Fig. 6A).
No signiﬁcant difference in cell cytotoxicity was observed ei-
ther in the lovastatin- and/or 27-hydroxycholesterol-treated cells,
or in medium containing FBS or LDS (Fig. 7). The visible cells in
lovastatin- and/or 27-hydroxycholesterol-treated cells were more
Fig. 4. The concentration of cholesterol (A) and incorporation of [3H]choline into
sphingomyelin (SM) (B) in the cultured endothelial cells treated with 50 nM of
lovastatin (Lov) alone and with 10 μM of mevalonic acid (Mev) or 25 μM of cho-
lesterol (Chol) for 60 h. Results are expressed as mean7S.E.M. of duplicate for each
independent determination in eight experiments. *Po0.05.
Fig. 5. The activities of CTP:phosphocholine cytidylyltransferase (CT) in the cul-
tured endothelial cells (A) and in supernatant (B) treated with 50 nM of lovastatin
(Lov) and/or 2 μM of 27-hydroxycholesterol (27OH) for 60 h and 1 h respectively.
Results are expressed as mean7S.E.M. of duplicate for each independent de-
termination in eight experiments.,*Po0.05.
Fig. 6. The activities of sphingomyelin (SM) synthase (A) and neutral sphingo-
myelinase (NSMase) (B) in the cultured endothelial cells treated with 50 nM of
lovastatin (Lov) and/or 2 μM of 27-hydroxycholesterol (27OH) for 60 h. Results are
expressed as mean7S.E.M. of duplicate for each independent determination in
eight experiments. *Po0.05.
Fig. 7. Effect of 50 nM of lovastatin (Lov) and/or 2 μM of 27-hydroxycholesterol
(27OH) on cell viability of the cultured endothelial cells after 60 h of the incubation
in the presence of fetal bovine serum (FBS) or lipoprotein deﬁcient serum (LDS) in
the culture medium, respectively. Results are expressed as mean7S.E.M. of du-
plicate for each independent determination in four experiments.
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In this study, we have shown that an increased sphingomyelin
caused by 27-hydroxycholesterol was signiﬁcantly reversed by
lovastatin.
It is known that phosphatidylcholine is a precursor for the
synthesis of sphingomyelin [29]. And sphingomyelin is synthe-
sized mainly by the phosphorylcholine headgroup's being directly
transferred from phosphatidylcholine to ceramide through
sphingomyelin synthase. We therefore ﬁrst studied the effect of
lovastatin on phosphatidylcholine. We found that lovastatin sig-
niﬁcantly reduced, at both dosages and time points, the in-
corporation of [3H]choline into phosphatidylcholine. This indicates
that lovastatin had an inhibitive effect on phosphatidylcholine
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synthesis takes place through the “CDP-choline” pathway where
CT is the rate-limiting enzyme, we measured the activity of this
enzyme. We found that CT activity was inhibited by lovastatin.
This indicates that the inhibitive effect of lovastatin occurred on
the de novo synthesis of phosphatidylcholine. This ﬁnding was
supported by a previous report that simvastatin, another HMG-
CoA reductase inhibitor with a similar chemical structure as lo-
vastatin, lowered activity of CT in HepG2 cells [30]. Since we did
not observe a dicreased CT activity by adding lovastatin into the
supernatant, we suggest that the inhibiting effect of lovastatin on
CT was indirect, and the mechanism needs to be further studied.
The data that lovastatin treatment resulted in a decrease of
sphingomyelin, but did not change the activities of sphingomyelin
synthase and NSMase shows that the reduced sphingomyelin was
not from the alteration of either sphingomyelin synthesis or its
metabolism in the presence of lovastatin, but was from the di-
minished phosphatidylcholine caused by lovastatin.
Sphingomyelinase (SMase) is known to classify into two major
groups, a lysosomal SMase called acid SMase (ASMase) and a cell
membrane-associated Mgþ þ-active SMase termed NSMase [31].
NSMase contributes to the catabolism of sphingomyelin to cer-
amide and phosphocholine [32] and is related not only to the
regulation of the concentration of sphingomyelin in the cell
membrane, but also to the aggregation of LDL, resulting in plaque
formation in atherosclerosis [33]. In this study we conﬁrmed that
the activity of NSMase was inhibited by 27-hydroxycholesterol
[34]. The inhibited activity of NSMase could result in an in-
tracellular sphingomyelin accumulation. Our data does not sup-
port a previous report that 27-hydroxycholesterol enhanced
phosphatidylcholine synthesis by activating CT in Chinese-ham-
ster ovary cells [35].
In this study, we found that lovastatin and 27-hydro-
xycholesterol affected sphingomyelin content by different me-
chanisms. That is, lovastatin decreased sphingomyelin content by
reducing phosphatidylcholine product, whereas 27-hydro-
xycholesterol increased sphingomyelin content by inhibiting
NSMase. Therefore it is possible when the decreasing effect of
lovastatin on sphingomyelin content was stronger than the sti-
mulative effect of 27-hydroxycholesterol, a reduced sphingomyelin
took place after lovastatin was added into the 27-hydro-
xycholesterol-treated cells.
To examine the possible relationship between the concentra-
tions of sphingomyelin and cholesterol in the presence of lovas-
tatin, we measured sphingomylin synthesis and cholesterol con-
tent after adding mevalonic acid and cholesterol, respectively, in
the culture medium containing lovastatin. The results showed that
the lovastatin-mediated decrease in cholesterol was completely
reversed in the cells incubated with mevalonic acid or cholesterol,
but diminished sphingomyelin was not reversed. Our ﬁndings in-
dicate that the lovastatin-mediated decrease in sphingomyelin was
not related to a diminished cholesterol concentration or synthesis.
A similar result obtained from a clinic study showed that rosu-
vastatin dose-dependently lowered plasma sphingolipids and
phospholipids and the decrease was independent of low-density
lipoprotein lowering [36]. This study does not suggest a parallel
association of the concentrations of sphingomyelin and choles-
terol, although their parallel accumulation occurred in a variety of
pathological conditions such as atherosclerosis and Niemann–Pick
disease [37,38]. Moreover, our ﬁndings that 27-hydroxycholesterol
enhanced sphingomyelin content, but decreased cholesterol con-
centration in the cultured cells [6,39] also indicate that their as-
sociation did not always exist.
In summary, we have presented evidence in this study that
(1) lovastatin induced a reduction of phosphatidylcholine con-
centration by inhibiting CT activity, resulting in a decrease ofsphingomyelin content; and (2) the decreased sphingomyelin was
not related to the diminished cholesterol concentration in the
presence of lovastatin.Conﬂict of interest
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